It's barely been open
It hasn't taken long for a Ribble Valley bistro to catch the eyes of the top dogs in the notoriously competitive culinary world. Fell Bistro in Longridge has been named as The Michelin Inspectors' Favourite New Restaurants.
READ MORE: Review - 263, Preston - a wild ride that takes in the world's poshest butter pie and Goosnargh fried chicken It is rated highly by customers, with a recent review on Facebook giving it five stars, praising their "outstanding" experience and the service as "wonderful" while the food was "out of this world." Oli, who has 17 years experience in fine dining and has previously worked in Michelin Starred restaurants, said the team are fell are "thrilled" to be included in the 'restaurant bible'.
"We're so pleased with the progress we have made since opening and it's all down to having such a passionate, hardworking team," he added.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Michelin-starred Glasgow restaurant shortlisted for 'restaurant of the year'A Glasgow restaurant has been shortlisted as 'restaurant of the year'.
Read more »
Best mattress on Amazon 2023: top bedding picks for easy orderingWe've found the best mattresses on Amazon to help you get a new bed quickly and easily.
Read more »
The best electric breast pumps for 2023 tested by mumsMother&Baby roundup the best electric breast pumps. This buyers' guide includes top picks from Medela, Lola&Lykke, and Tommee Tippee.
Read more »
period grandeurLlandrinio Hall, in Llandrinio near Llanymynech, enjoys a rural setting with wonderful views. On the market with Savills with a guide price of £1,350,000, the hall is believed to be the oldest extant brick-built building in Montgomeryshire.
Read more »
19 best maternity leggings that you can wear all dayMother&Baby round up the best maternity leggings. In this buyer's guide, you'll find top picks from H&M, Boohoo, Seraphine and many more.
Read more »
The sense of stopping migraine prophylaxis - The Journal of Headache and PainIntroduction Migraine prophylactic therapy has changed over recent years with the development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. As new therapies emerged, leading headache societies have been providing guidelines on the initiation and escalation of such therapies. However, there is a lack of robust evidence looking at the duration of successful prophylaxis and the effects of therapy discontinuation. In this narrative review we explore both the biological and clinical rationale for prophylactic therapy discontinuation to provide a basis for clinical decision-making. Methods Three different literature search strategies were conducted for this narrative review. These include i) stopping rules in comorbidities of migraine in which overlapping preventives are prescribed, notably depression and epilepsy; ii) stopping rules of oral treatment and botox; iii) stopping rules of antibodies targeting the CGRP (receptor). Keywords were utilized in the following databases: Embase, Medline ALL, Web of Science Core collection, Cochran Central Register of Controlled Trials, and Google Scholar. Discussion Reasons to guide decision-making in stopping prophylactic migraine therapies include adverse events, efficacy failure, drug holiday following long-term administration, and patient-specific reasons. Certain guidelines contain both positive and negative stopping rules. Following withdrawal of migraine prophylaxis, migraine burden may return to pre-treatment level, remain unchanged, or lie somewhere in-between. The current suggestion to discontinue CGRP(-receptor) targeted mAbs after 6 to 12 months is based on expert opinion, as opposed to robust scientific evidence. Current guidelines advise the clinician to assess the success of CGRP(-receptor) targeted mAbs after three months. Based on excellent tolerability data and the absence of scientific data, we propose if no other reasons apply, to stop the use of mAbs wh
Read more »